drugset
Drugs / MVA-CMDR
last change Dec 2024 re-read 9 days ago

MVA-CMDR

also known as Modified Vaccinia Virus Ankara (MVA-CMDR) · MVA-CMDR Vaccine

Vaccine

Developed for
HIV infectious disease
Investigated by
Karolinska Institutet · National Institute of Allergy and Infectious Diseases (NIAID) · Armed Forces Research Institute of Medical Sciences, Thailand · Bambino Gesù Hospital and Research Institute · CHAVI · CONRAD
+27 more · Case Western Reserve University · Centre Hospitalier Universitaire Vaudois · Chulalongkorn University · EuroVacc Foundation · Gilead Sciences · HIV Vaccine Trials Network · Henry M. Jackson Foundation for the Advancement of Military Medicine · IPPOX Foundation · Imperial College London · Instituto Nacional de Saúde, Mozambique · International AIDS Vaccine Initiative · Johns Hopkins University · King's College London · Leidos Biomedical Research, Inc. · Ludwig-Maximilians - University of Munich · MHRP · MRC/UVRI and LSHTM Uganda Research Unit · Medical Research Council, South Africa · Muhimbili University of Health and Allied Sciences · National Institute for Medical Research, Tanzania · PENTA Foundation · Rockefeller University · U.S. Army Medical Research and Development Command · University College, London · University of Miami · University of Padova · Walter Reed Army Institute of Research (WRAIR)

Trials 6

today NCT04301154 · Ph 1 NCT04066881 · Ph 2 NCT02296541 · Ph 1 NCT01889719 · Ph 1 NCT01260727 · Ph 1 NCT00376090 · Ph 1
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT04301154 Feb 2022 → Oct 2023 HIV infectious disease Henry M. Jackson Foundation for the Advancement of Military Medicine Completed No outcome recorded
Phase 1 NCT02296541 Dec 2014 → Nov 2016 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01889719 Jan 2014 → May 2015 HIV infectious disease Rockefeller University Completed No outcome recorded
Phase 1 NCT01260727 Feb 2010 → Dec 2013 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00376090 Jul 2005 → Dec 2008 HIV infectious disease U.S. Army Medical Research and Development Command Completed No outcome recorded
Phase 21 trial
Phase 2 NCT04066881 Dec 2020 → Dec 2024 HIV infectious disease MRC/UVRI and LSHTM Uganda Research Unit Completed No outcome recorded
Comparator or background therapy1 trial
Phase 1 NCT01407497 Comparator Aug 2011 → Mar 2013 HIV infectious disease Instituto Nacional de Saúde, Mozambique Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as MVA-CMDR “MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to...” NCT04066881 ↗
6

“MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume...” NCT01260727 ↗

NCT01889719 ↗

NCT01407497 ↗

NCT00376090 ↗

NCT04301154 ↗

NCT02296541 ↗
Known as Modified Vaccinia Virus Ankara (MVA-CMDR) “Modified Vaccinia Virus Ankara (MVA-CMDR)” NCT02296541 ↗
Known as MVA-CMDR Vaccine “MVA-CMDR Vaccine” NCT01260727 ↗
Modality Vaccine “a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara viral vector expressing HIV-1 genes env/gag/pol.” PMID 21085591 ↗ Nov 2010
Route Intramuscular “intra-muscularly (IM; 10(7) or 10(8) pfu)” PMID 21085591 ↗ Nov 2010